Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to inhibit pyroptosis and apoptosis, which play important roles in the development and progression of contrast-induced acute kidney injury (CI-AKI). However, to the best of our knowledge, no studies have investigated th...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2022/1638209 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850227596488343552 |
|---|---|
| author | Yu Ma Lei Zha Qi Zhang Lu Cao Ru Zhao Jing Ma Kai Hou Yue Pan Hongliang Cong Ximing Li |
| author_facet | Yu Ma Lei Zha Qi Zhang Lu Cao Ru Zhao Jing Ma Kai Hou Yue Pan Hongliang Cong Ximing Li |
| author_sort | Yu Ma |
| collection | DOAJ |
| description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to inhibit pyroptosis and apoptosis, which play important roles in the development and progression of contrast-induced acute kidney injury (CI-AKI). However, to the best of our knowledge, no studies have investigated the potential effect of PCSK9 inhibitors on the prevalence of CI-AKI after percutaneous coronary intervention (PCI). This study aimed to determine whether PCSK9 inhibitors are associated with the prevalence of CI-AKI. The medical records of 309 (mean age, 63.35 years; 71.84% male) patients with acute myocardial infarction who underwent PCI at our institution were retrospectively analyzed. Overall, 149 and 160 patients were assigned to the evolocumab and control groups, respectively. Serum creatinine levels were examined preoperatively and 24–72 h postoperatively and compared between groups. Data were grouped according to the occurrence of CI-AKI, and a univariate analysis was conducted to exclude suspected influencing factors that led to CI-AKI occurrence. After adjusting for confounding factors, a logistic regression analysis was performed to assess the association between evolocumab administration (independent variable) and CI-AKI occurrence (dependent variable). The prevalence of CI-AKI was significantly lower in the evolocumab group (6.7%) than in the control group (20.0%; p<0.01).We further evaluated the correlation between exposure factor and outcome. The relative risk(RR) between the use of evolocumab and the occurrence of CI-AKI was 0.34(95% CI 0.17-0.66,p<0.01).This result indicate a significant association between the use of evolocumab and a reduction in the incidence of CI-AKI.The logistic regression analysis results revealed that evolocumab was significantly associated with CI-AKI. The use of PCSK9 inhibitors, hydration therapy, and statin administration appears promising for preventing CI-AKI in patients with acute myocardial infarction undergoing PCI. |
| format | Article |
| id | doaj-art-275b668a55bc4ab7a6ec1a8d7bec9d5e |
| institution | OA Journals |
| issn | 2090-0597 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-275b668a55bc4ab7a6ec1a8d7bec9d5e2025-08-20T02:04:48ZengWileyCardiology Research and Practice2090-05972022-01-01202210.1155/2022/1638209Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention TherapyYu Ma0Lei Zha1Qi Zhang2Lu Cao3Ru Zhao4Jing Ma5Kai Hou6Yue Pan7Hongliang Cong8Ximing Li9Department of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyTianjin Institute of Cardiovascular DiseasesTianjin Medical UniversityDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to inhibit pyroptosis and apoptosis, which play important roles in the development and progression of contrast-induced acute kidney injury (CI-AKI). However, to the best of our knowledge, no studies have investigated the potential effect of PCSK9 inhibitors on the prevalence of CI-AKI after percutaneous coronary intervention (PCI). This study aimed to determine whether PCSK9 inhibitors are associated with the prevalence of CI-AKI. The medical records of 309 (mean age, 63.35 years; 71.84% male) patients with acute myocardial infarction who underwent PCI at our institution were retrospectively analyzed. Overall, 149 and 160 patients were assigned to the evolocumab and control groups, respectively. Serum creatinine levels were examined preoperatively and 24–72 h postoperatively and compared between groups. Data were grouped according to the occurrence of CI-AKI, and a univariate analysis was conducted to exclude suspected influencing factors that led to CI-AKI occurrence. After adjusting for confounding factors, a logistic regression analysis was performed to assess the association between evolocumab administration (independent variable) and CI-AKI occurrence (dependent variable). The prevalence of CI-AKI was significantly lower in the evolocumab group (6.7%) than in the control group (20.0%; p<0.01).We further evaluated the correlation between exposure factor and outcome. The relative risk(RR) between the use of evolocumab and the occurrence of CI-AKI was 0.34(95% CI 0.17-0.66,p<0.01).This result indicate a significant association between the use of evolocumab and a reduction in the incidence of CI-AKI.The logistic regression analysis results revealed that evolocumab was significantly associated with CI-AKI. The use of PCSK9 inhibitors, hydration therapy, and statin administration appears promising for preventing CI-AKI in patients with acute myocardial infarction undergoing PCI.http://dx.doi.org/10.1155/2022/1638209 |
| spellingShingle | Yu Ma Lei Zha Qi Zhang Lu Cao Ru Zhao Jing Ma Kai Hou Yue Pan Hongliang Cong Ximing Li Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy Cardiology Research and Practice |
| title | Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy |
| title_full | Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy |
| title_fullStr | Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy |
| title_full_unstemmed | Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy |
| title_short | Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy |
| title_sort | effect of pcsk9 inhibitor on contrast induced acute kidney injury in patients with acute myocardial infarction undergoing intervention therapy |
| url | http://dx.doi.org/10.1155/2022/1638209 |
| work_keys_str_mv | AT yuma effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy AT leizha effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy AT qizhang effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy AT lucao effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy AT ruzhao effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy AT jingma effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy AT kaihou effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy AT yuepan effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy AT hongliangcong effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy AT ximingli effectofpcsk9inhibitoroncontrastinducedacutekidneyinjuryinpatientswithacutemyocardialinfarctionundergoinginterventiontherapy |